Identifying pseudohypertriglyceridemia in clinical practice

Q Medicine

Clinical Lipidology Pub Date : 2014-12-01 DOI:10.2217/clp.14.52

J. Backes, T. Dayspring, D. Hoefner, J. Contois, J. Mcconnell, P. Moriarty

引用次数: 13

Abstract

Abstract Isolated asymptomatic glycerol kinase deficiency (GKD) or ‘pseudohypertriglyceridemia’, is an X-linked recessive disorder resulting in hyperglyceroluria and hyperglycerolemia. Patients typically present with hypertriglyceridemia, which is unresponsive to therapy. The falsely elevated triglycerides are a result of clinical laboratories utilizing glycerol levels to report triglyceride concentrations. Glycerol blanking will account for the excess glycerol and provide accurate triglyceride measures. Pseudohypertriglyceridemia is linked to glucose impairment and other forms of GKD involving childhood metabolic crises and developmental limitations. Identifying patients with pseudohypertriglyceridemia prevents overestimation of cardiovascular risk and exposure to unnecessary lipid-altering agents; and heightens the awareness of the potential for symptomatic GKD in male offspring. We urge clinical labs to provide a glycerol-blanked triglyceride measurement for known or suspected pseudohypertriglyceridemia.

查看原文本刊更多论文

在临床实践中识别假性高甘油三酯血症

孤立性无症状甘油激酶缺乏症(GKD)或“假性高甘油三酯血症”，是一种x连锁隐性疾病，导致高甘油尿症和高甘油血症。患者通常表现为高甘油三酯血症，对治疗无反应。错误升高的甘油三酯是临床实验室利用甘油水平报告甘油三酯浓度的结果。甘油空白将说明多余的甘油和提供准确的甘油三酯测量。假性高甘油三酯血症与葡萄糖损伤和其他形式的GKD有关，涉及儿童代谢危机和发育限制。识别假性高甘油三酯血症患者可以防止高估心血管风险和暴露于不必要的脂质改变药物;并提高了对男性后代可能出现症状性GKD的认识。我们敦促临床实验室提供甘油空白甘油三酯测量已知或可疑的假性高甘油三酯血症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.